Charles Jones is the founder of Volastra Therapeutics. Volastra Therapeutics has raised $84M in total funding. Latest round: Series A. Based in New York, NY.
Charles Hugh-Jones, M.D., served as the first CEO of Volastra Therapeutics from 2020 to 2023. During his tenure, he guided the company through its seed financing, secured $44 million in extended seed funding, and oversaw a $60 million Series A round. He also established key partnerships with Microsoft and Bristol Myers Squibb.
Full founder directory · Investor directory · Company funding database · Fundraising library